Published in
Elsevier, Journal of the American College of Cardiology, 11(71), p. A1398
DOI: 10.1016/s0735-1097(18)31939-9
American Society of Hematology, Blood Advances, 6(2), p. 715-730, 2018
DOI: 10.1182/bloodadvances.2017013573
Links
Tools
Inhibitory mechanisms of very low–dose rivaroxaban in non–ST-elevation myocardial infarction
Journal article published in 2018 by
Patrick Muenzer,
Patrick Münzer,
Nada Alnaggar,
Sascha Geue,
Oliver Borst,
Roland Tegtmeyer,
Dominik Rath,
Michal Droppa,
Peter Seizer,
Stefan Heitmeier,
Johan W. M. Heemskerk 
,
Lisa K. Jennings,
Hugo Ten Cate,
Robert F. Storey,
Dominick J. Angiolillo
and other authors.
,
Lisa K. Jennings,
Hugo Ten Cate,
Robert F. Storey,
Dominick J. Angiolillo
and other authors.
This paper is made freely available by the publisher.
Full text: Download
Published version:
archiving forbidden
Data provided by 
Abstract
Key Points VLD rivaroxaban significantly reduces platelet-dependent thrombin generation and thrombus formation on top of DAPT in patients with ACS. Adjunctive treatment with VLD rivaroxaban additionally reduced TG and thrombus formation in both clopidogrel responders and nonresponders.